The drugmaker’s CEO, Lars Fruergaard Jorgensen, said at a Reuters event in late August that it could “take quite some years” before the shortages end as demand continues to surge for the medications.
Novo Nordisk saw a 29 percent increase in sales in the first half of 2023, which led to “periodic supply constraints and related drug shortage notifications.” The company expects sales to grow about 30 percent throughout the next year.
One Ozempic solution and three lower-dose Wegovy presentations are in limited supply, according to the FDA’s drug shortage database. The Ozempic shortage is expected to end by the end of 2023, and no resupply date was provided for Wegovy.
